论文部分内容阅读
目的:比较米非司酮不同剂量对子宫内膜异位症(EMs)患者术后症状缓解的临床疗效。方法:选取2013年1月—2015年6月间给予保守手术治疗的EMs患者104例,根据患者术后米非司酮的用量将其分为小剂量组和大剂量组(每组52例),比较两组患者治疗后的性激素和相关激素的测得值、症状完全缓解率和复发率。结果:治疗后两组患者的血清雌二醇(E_2)和孕酮值低于治疗前(P<0.05),两组患者的血清黄体生成素(LH)值高于治疗前(P<0.05);小剂量组患者治疗后的血清E_2、孕酮值低于大剂量组(P<0.05),血清LH值高于大剂量组(P<0.05);两组患者的血清促卵泡激素(FSH)值经比较其差异无统计学意义(P>0.05);小剂量组患者症状完全缓解率为84.61%高于大剂量组为65.38%(P<0.05),复发率为1.92%低于大剂量组为15.38%(P<0.05)。结论:米非司酮小剂量用于治疗EMs患者术后,可改善机体性激素和相关激素水平,症状的缓解率和复发率优于大剂量的治疗。
Objective: To compare the clinical efficacy of different doses of mifepristone on postoperative symptom relief in patients with endometriosis (EMs). Methods: One hundred and four patients with EMs who underwent conservative surgery between January 2013 and June 2015 were selected and divided into two groups according to the amount of mifepristone: low-dose group and high-dose group (52 cases in each group) The measured values of sex hormones and related hormones after treatment were compared between the two groups. The rate of complete remission and recurrence was compared. Results: Serum estradiol (E2) and progesterone levels were lower in both groups after treatment than those before treatment (P <0.05), serum LH levels in both groups were significantly higher than those before treatment (P <0.05) (P <0.05). Serum LH was higher than that of the high-dose group (P <0.05). Serum follicle-stimulating hormone (FSH) (P> 0.05). The complete remission rate was 84.61% in the low dose group and 65.38% (P <0.05) in the high dose group, the recurrence rate was 1.92% lower than the high dose group 15.38% (P <0.05). CONCLUSION: Mifepristone is effective in the treatment of patients with EMs after surgery, which can improve the level of sex hormones and related hormones, and the rate of symptom relief and recurrence is superior to that of high-dose treatment.